Hexarelinsafety profile & UK regulatory status

This page summarises the published safety profile, contraindications, formulation interactions, and UK regulatory status for Hexarelin as reported in the pre-clinical research literature. It is a research-orientation reference and not a clinical safety assessment. Hexarelin is not licensed as a medicine in the United Kingdom and may not be supplied or administered to humans outside an authorised clinical-trial framework.

Safety profile

Acute safety data for hexarelin come primarily from the 1990s Mediolanum clinical-development programme and subsequent academic research. The acute adverse-event profile includes mild transient flushing and warmth following IV bolus administration, occasional mild headache, and infrequent transient hypotension at higher IV doses. Subcutaneous administration produces a milder acute profile with predominantly injection-site reactions. The principal pharmacodynamic safety considerations relate to the GHRP-class GH-axis effects — cortisol and prolactin elevation. Hexarelin produces measurable but moderate cortisol elevation (2- to 3-fold transient rises at saturating doses), substantially smaller than GHRP-6 (3- to 4-fold rises) but materially larger than ipamorelin (no measurable cortisol effect). Prolactin elevation is similarly intermediate. These off-target effects do not produce clinically significant adverse consequences from acute single-dose administration but should be considered in research where adrenal-axis or prolactin endpoints are being measured. Chronic-dosing safety experience is limited but the principal pharmacological concern is the GH-axis desensitisation with sustained somatotroph GHSR-1a activation. Repeated daily dosing across days-to-weeks produces progressive attenuation of GH release — a tachyphylactic response that limits practical chronic-replacement utility. Theoretical concerns about chronic GH/IGF-1 elevation parallel other GH-axis peptides: oncogenic risk through IGF-1R activation, insulin resistance, and diabetic retinopathy progression. The direct cardiac CD36 receptor binding raises theoretical cardiovascular considerations specific to hexarelin. Acute cardiovascular effects in published trials have been favourable (cardioprotective in ischaemia models), but the chronic effects of pharmacological CD36 modulation are incompletely characterised. Researchers using hexarelin in cardiac-disease populations or models should monitor cardiac endpoints accordingly. Hexarelin's hexapeptide structure (887 Da) with non-standard amino acids carries low immunogenicity risk. Anti-drug antibodies have not been a significant issue in published data. Sterility and endotoxin content of research-chemical-grade preparations remain the dominant practical safety variables. No serious immediate adverse events (anaphylaxis, severe hypotension, cardiac events) have been documented at research-protocol doses.

UK regulatory status

Hexarelin is not authorised as a medicinal product by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and holds no marketing authorisation in any jurisdiction. It is not a controlled substance under the Misuse of Drugs Act 1971. Hexarelin is captured by the World Anti-Doping Agency (WADA) Prohibited List under category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) as a growth-hormone secretagogue. Athletes subject to anti-doping testing should treat hexarelin and all GHRP-class peptides as prohibited both in-competition and out-of-competition regardless of claimed research purpose. MHRA enforcement actions concerning hexarelin supply specifically have not been published in the public domain. Generic warnings on unlicensed peptide supply for human use apply. Research-grade hexarelin for in-vitro and animal research is available from research-chemical suppliers; possession for bona fide laboratory research is generally unrestricted in the UK. Supply or administration to humans outside an authorised clinical-trial framework engages the Human Medicines Regulations 2012 and is generally an offence. For animal research under ASPA (Animals (Scientific Procedures) Act 1986), hexarelin work in vertebrates requires standard project and personal licences from the Home Office Drugs and Firearms Licensing Unit.

What 'research-use-only' means in the UK

The UK regulatory position on research peptides sits across four distinct frameworks: MHRA medicines licensing, the Human Medicines Regulations 2012, the Misuse of Drugs Act 1971, and the WADA Prohibited List. Hexarelin is not an MHRA-licensed medicine; possession for bona fide in-vitro or ex-vivo laboratory research is generally lawful, while supply or administration to humans engages the Human Medicines Regulations and is generally an offence. For animal-research use, additional permissions are required under the Animals (Scientific Procedures) Act 1986 (ASPA).

For the comprehensive UK regulatory reference covering all four frameworks, see the UK research peptide regulation 2026 reference.

Practical safety considerations for research

Sterility and endotoxin content of research-grade preparations remain the dominant practical safety variables for any injectable in-vivo work, regardless of the intrinsic safety profile of the active peptide. Batch-to-batch verification of HPLC purity and identity (by mass spectrometry where possible) and endotoxin testing by limulus amebocyte lysate (LAL) assay or recombinant Factor C (rFC) assay are standard due-diligence expectations. For research with vertebrate animals in the UK, ASPA project and personal licences are mandatory and the work must pass a local Animal Welfare and Ethical Review Body assessment.

For full Hexarelin research context including mechanism, study citations, and references, see the main Hexarelin research profile. For dosing and pharmacokinetic context, see the dosing reference and half-life reference pages.